Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel circulating protein,which plays an important role in the regulation of cholesterol metabolism.Over the past decade,experimental and clinical studies have established that over-or poor expression of PCSK9 has a key impact not only on circulating PCSK9 and low density lipoprotein cholesterol (LDL-C) levels but also on cardiovascular risk and atherosclerotic process.Since the first discovery of PCSK9-related gene in 2003,factors that can influence circulating PCSK9 concentration are of great interest in a variety of medical fields,especially in pharmacology.In this review we focus on the impact of lipid-lowering drugs on circulating PCSK9 concentration and its clinical implications in order to provide new considerations for optimizing current strategies with regard to cholesterol control.%前蛋白转化酶枯草溶菌素/kexin9型(PCSK9)是一种新型循环蛋白,在胆固醇代谢调节过程中起着重要作用.在过去十几年中,实验研究和临床研究已经证实,PCSK9过度表达或低表达不仅会影响循环PCSK9和低密度脂蛋白胆固醇(LDL-C)水平,还会对心血管风险和动脉粥样硬化产生重大影响.自从2003年首次发现PCSK9相关基因以来,可以影响循环PCSK9浓度的因素引起了医学界各方的极大关注,尤其是药理学界.本综述重点关注降脂药对循环PCSK9浓度的影响及其临床意义,以期为优化当前的胆固醇控制策略提供思路.
展开▼
